716 results on '"Mallon, Patrick"'
Search Results
2. Challenges in assessing the immunization status of adults in Germany—lessons from a population-based VACCELERATE survey on polio vaccination
3. Impact of vaccination and variants of concern on long COVID clinical phenotypes
4. Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time
5. Rapid antigen-based and rapid molecular tests for the detection of SARS-CoV-2: a rapid review with network meta-analysis of diagnostic test accuracy studies
6. Early inflammatory profiles predict maximal disease severity in COVID-19: An unsupervised cluster analysis
7. Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)
8. Associations between host microbiome and inflammation suggest role for host microbiome in driving COVID-19 disease severity
9. Predicting the next pandemic: VACCELERATE ranking of the WorldHealth Organization's Blueprint forAction toPreventEpidemics
10. Antigen specific T cells in people with obesity at five months following ChAdOx1 COVID-19 vaccination
11. VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe
12. A single centre experience of prosthetic joint infection outcomes with outpatient parenteral antimicrobial therapy
13. Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1)
14. Prediction of low pulse oxygen saturation in COVID-19 using remote monitoring post hospital discharge
15. Identification of inflammatory clusters in long-COVID through analysis of plasma biomarker levels
16. An enhanced participant information leaflet and multimedia intervention to improve the quality of informed consent to a randomised clinical trial enrolling people living with HIV and obesity: a protocol for a Study Within A Trial (SWAT)
17. Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction
18. Association between inflammatory biomarker profiles and cardiovascular risk in individuals with and without HIV
19. HIV and comorbidities – the importance of gut inflammation and the kynurenine pathway
20. HIV and co-morbidities – an evolving, global view
21. Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications
22. Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization
23. Challenges in assessing the immunization status of adults in Germany – Lessons from a population-based VACCELERATE survey on polio vaccination
24. Predicting the next pandemic: VACCELERATE ranking of the World Health Organization's Blueprint for Action to Prevent Epidemics
25. A multinational case series describing successful treatment of persistent SARS-CoV-2 infection caused by Omicron sublineages with prolonged courses of nirmatrelvir/ritonavir.
26. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
27. Obesity in HIV infection: host-pathogen interaction
28. Weight gain before and after switch from TDF to TAF in a U.S. cohort study
29. Biomarkers to predict cardiovascular disease in people living with HIV
30. The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium
31. 2338. Robust and Persistent B Cell Responses Following Third Dose SARS-CoV-2 Vaccine Determine Protection from COVID-19
32. 1346. Genetic Variation at the Interferon λ Locus and Association with Clinical Outcome and Severity of COVID-19
33. 2356. Close correlation of RBD with Live Viral Neutralising Capacity Across Variants and Time Supports Use of RBD Thresholds to Predict Protective Host Immunity
34. Clinical management of ageing people living with HIV in Europe: the view of the care providers
35. Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial
36. A Multinational Case Series Describing Successful Treatment of Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection Caused by Omicron Sublineages With Prolonged Courses of Nirmatrelvir/Ritonavir.
37. Anticholinergic medications associated with falls and frailty in people with HIV.
38. Robust cross-cohort gut microbiome associations with COVID-19 severity
39. Establishing severe acute respiratory infection (SARI) surveillance in a sentinel hospital, Ireland, 2021 to 2022
40. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial
41. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial
42. Dysregulated early transcriptional signatures linked to mast cell and interferon responses are implicated in COVID-19 severity
43. Long COVID: Clinical characteristics, proposed pathogenesis and potential therapeutic targets
44. Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit
45. Are we ready to RESPOND that the question of abacavir's role in cardiovascular disease events is settled?
46. The predictors of pain extent in people living with HIV
47. Comorbidity indices in people with HIV and considerations for coronavirus disease 2019 outcomes
48. Associations Between Widespread Pain and Sleep Quality in People With HIV
49. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study
50. The COVIRL-001 Trial: A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non- critical, SARS-CoV-2 PCR-positive population not requiring immediate resuscitation or ventilation but who have evidence of clinical decline: A structured summary of a study protocol for a randomised controlled trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.